Story no.231OngoingHealthLowCôte-d'Or +128 Oct → 3 Nov8 facts · 52 art.
Arrival of Wegovy in tablet form and tensions around anti-obesity treatments
In late October 2026, the anti-obesity treatment Wegovy arrives in tablet form in French pharmacies, with details on its price, availability and prescription. In early November, Professor Emmanuel Disse of the Hospices civils de Lyon speaks on the role of drug treatments for obesity compared with bariatric surgery. Four and a half months after reimbursement of Mounjaro and Wegovy began, waiting times for specialist consultations reach up to 18 months and a parallel market is developing. A patient treated with Mounjaro for three years says she has lost 50 kg.
In brief
Ongoing story bringing together 8 events nationwide, followed from 28 October 2026 to 3 November 2026. 52 articles from 22 sources (health); last updated on 3 November 2026 at 16:15.
47 articles of rated outlets · 5 unrated outside the bar · 22 sources (52 art.) · the three sides talk about it · outlets: left 4, centre 15, right 2
Angle comparison for the whole story
All three sides cover the arrival of Wegovy in tablet form, but the left emphasizes industrial competition and reimbursement conditions, the center develops waiting times, the parallel market and patient testimonies, while the right highlights the non-reimbursable nature and practical information (price, side effects).
Left
Highlights the rivalry between Novo Nordisk and Eli Lilly on a fast-growing global market, as well as the lack of reimbursement for the pills and the side effects to be aware of.
Centre
Develops the concrete consequences: waiting times of up to 18 months, the parallel market, the position of drug treatments compared with bariatric surgery and patient testimonies.
Right
Emphasizes the non-reimbursable nature of oral Wegovy and offers a practical format listing price, side effects and reimbursement.
Written by an AI from headlines and extracts only of all events in the story · 2 Nov, 03h41
Confirmed by several sources(5)
- 7
Wegovy tablets are marketed in France from 2 November.
7 independent sourcesBFMTV / RMC, Paris-Normandie, Midi Libre, 20 Minutes, La Dépêche du Midi +4
- 5
Oral Wegovy is sold at a recommended price of 169 euros per month and is not reimbursed.
5 independent sourcesMidi Libre, Le Moniteur des pharmacies, 20 Minutes, Libération, Les Échos
- 2
Waiting times in specialist consultations authorized to prescribe anti-obesity drugs reach up to 18 months.
2 independent sourcesLes Échos, Le Progrès, Le Bien Public, Le Dauphiné libéré, L'Est Républicain
- 2
Oral Wegovy contains semaglutide, a GLP-1 receptor agonist.
2 independent sourcesParis-Normandie, TF1 Info / LCI
- 2
Injectable Wegovy has been available in France since 2024 and reimbursed under conditions since June 2026.
2 independent sourcesLe Progrès, TF1 Info / LCI
Single source so far(5)
- The European Commission authorized oral Wegovy on 15 July 2026. (according to Paris-Normandie)
- A parallel market for these drugs is thriving, difficult to quantify. (according to Le Progrès, Le Bien Public, Le Dauphiné libéré, L'Est Républicain)
- Professor Emmanuel Disse said: "The more patients we treat, the more bariatric surgery there will be." (according to Le Progrès, Le Bien Public, L'Est Républicain)
- Meta Tshiteya, treated with Mounjaro for three years, has lost 50 kg. (according to L'Est Républicain, Le Dauphiné libéré, Le Progrès)
AI cross-check of the headlines and extracts of 28 articles (18 outlets) · “confirmed” = reported by at least two independent outlets · 1 Nov, 22h41
Checked on the web(3)
- Not confirmed at this stage
Wegovy tablets are marketed in France from 2 November.
Sources: ansm.sante.fr(official), www2.assemblee-nationale.fr(official), rtl.fr, franceinfo.fr, lagazettefrance.fr
1 Nov, 22h44
- Not confirmed at this stage
Oral Wegovy is sold at a recommended price of 169 euros per month and is not reimbursed.
Sources: ansm.sante.fr(official), rtl.fr, franceinfo.fr, lagazettefrance.fr, prescrire.org
1 Nov, 22h44
- Not confirmed at this stage
The European Commission authorized oral Wegovy on 15 July 2026.
Sources: lagazettefrance.fr, prescrire.org, ameli.fr, qare.fr, 20minutes.fr
1 Nov, 22h44
Automatic web search, official sources first · “contradicted” only when an official source is cited
Timeline
newest firstOutlets:LeftCentreRightUncategorised· badge = severity
- 16h15
LatestLes anti-obésité modifient les habitudes alimentaires des patients
Une étude du cabinet Bain portant sur des milliers de patients note une baisse de consommation de produits sucrés et de snacks chez les personnes traitées par anti-obésité.
Le MondeCentre-left
- 12h27
Traitement anti-obésité en comprimé : des effets secondaires sur l'économie
Une analyse revient sur l'arrivée d'un traitement anti-obésité disponible en comprimé et sur ses répercussions économiques, au-delà de ses effets secondaires médicaux.
La Voix du NordCentre
- 07h00
Les douanes renforcent les contrôles face au trafic de coupe-faims comme le Wegovy
Depuis la mise sur le marché du Wegovy en comprimés, les douanes multiplient les contrôles de colis pour freiner les achats illégaux de médicaments coupe-faim sur des sites clandestins. Ces produits figurent parmi les plus saisis.
TF1 Info / LCICentre
In figures
Further reading
Organisations cited
Places cited
Go up the thread
Events in the story
- Les anti-obésité modifient les habitudes alimentaires des patients3 Nov
- Traitement anti-obésité en comprimé : des effets secondaires sur l'économie3 Nov
- Les douanes renforcent les contrôles face au trafic de coupe-faims comme le Wegovy3 Nov
- Wegovy tablet arrives in French pharmacies2 Nov
- Dijon : les limites du remboursement des traitements anti-obésité2 Nov
- Testimony from a patient treated with Mounjaro who lost 50 kg1 Nov
- Anti-obesity drugs: up to 18 months' wait for consultations1 Nov
- Obesity drug treatments: Lyon doctor speaks on their place compared with surgery1 Nov
Affected departments